Last update 04 Nov 2024

Fentanyl

Last update 04 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration.

Drug Type

Small molecule drug

Synonyms

AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN)

+ [36]

Target

Opioid receptors

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Cancer PainChronic PainPain

Inactive Indication

Acute PainAdvanced cancerBreakthrough Pain+ [12]

Originator Organization

Janssen Global Services LLC

Active Organization

Janssen Pharmaceutical KK

Yichang Humanwell Pharmaceuticals Co., Ltd.

Janssen Pharmaceutica NV

+ [4]

Inactive Organization

Janssen Pharmaceuticals, Inc.Janssen Research & Development LLC

INSYS Therapeutics, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

US (07 Aug 1990),

HypoventilationPain, Postoperative

Regulation-

Structure

Molecular FormulaC22H28N2O

InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N

CAS Registry437-38-7

1,275

Clinical Trials associated with Fentanyl

NCT06650371 / Not yet recruitingNot ApplicableIIT

Comparative Study Between the Performance of Opioid Free Anesthesia Versus Conventional Opioid Based Anesthesia Regarding Achievement of Enhanced Recovery in Laparoscopic Bariatric Surgeries

This Study aims to evaluate the efficacy of opioid free general anesthesia in achieving enhanced recovery after surgery (ERAS) in laparoscopic bariatric surgery in terms of post-operative recovery time, cumulative pethidine consumption and number of episodes of postoperative nausea and vomiting(PONV).

Start Date20 Nov 2024

Sponsor / Collaborator

Ain Shams University

CTRI/2024/10/074657 / Not yet recruitingNot Applicable

Comparison of Isobaric 0.75 Ropivacaine with fentanyl versus Hyperbaric 0.5 Bupivacaine with fentanyl in Spinal anaesthesia for infraumbilical surgeries. - nil

Start Date14 Oct 2024

Sponsor / Collaborator-

NCT06576830 / Not yet recruitingPhase 4IIT

Single-Dose Intraoperative Methadone for Pain Management in Pediatric Tonsillectomy: A Randomized Double Blind Clinical Trial

The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following tonsillectomy surgery in children and adolescents.

Start Date01 Oct 2024

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with Fentanyl

100 Translational Medicine associated with Fentanyl

100 Patents (Medical) associated with Fentanyl

22,520

Literatures (Medical) associated with Fentanyl

01 Apr 2025·DEN open

Sedative effects of propofol and risk factors for excessive sedation in the endoscopic treatment of biliary and pancreatic diseases

Article

Author: Chatto, Mark ; Yamashige, Daiki ; Hijioka, Susumu ; Hara, Hidenobu ; Hagiwara, Yuya ; Agarie, Daiki ; Fukuda, Soma ; Yagi, Shin ; Saito, Yutaka ; Okusaka, Takuji ; Okamoto, Kouhei ; Nagashio, Yoshikuni ; Takasaki, Tetsuro ; Morizane, Chigusa ; Sone, Miyuki ; Maruki, Yuta

Abstract:

Objectives:

The safety and effectiveness of propofol in more complex endoscopic procedures, such as endoscopic retrograde cholangiopancreatography, remain unknown. Thus, we aimed to evaluate propofol sedation during endoscopic cholangiopancreatography, ultrasound‐guided intervention, and gastroduodenal stenting and examine risk factors for excessive sedation.

Methods:

We retrospectively analyzed data from 870 patients who underwent endoscopic treatment with propofol sedation for biliary and pancreatic disease between October 2020 and September 2021. Sedation included propofol and fentanyl, with continuous monitoring of vital signs and the bispectral index. The assessed risk factors included age, complications, body mass index, treatment duration, and specialty.

Results:

Distal bile duct treatment (n = 367), hilar bile duct treatment (n = 197), post‐small‐intestinal reconstruction treatment (n = 75), endoscopic ultrasound‐guided intervention (n = 140), and gastrointestinal obstruction treatment (n = 91) were performed. The rates of excessive sedation, hypoxemia, and hypotension were 7.8%, 6.0%, and 1.8%, respectively. Post‐small‐intestinal reconstruction treatment had the highest incidence rate of excessive sedation (16%), whereas endoscopic ultrasound‐guided intervention had the lowest incidence rate (4.3%). Multivariate analysis revealed significant associations between excessive sedation and comorbid sleep apnea, obesity, and prolonged procedural time.

Conclusions:

Obesity, sleep apnea syndrome, and prolonged procedure time are risk factors for excessive sedation related to propofol use. Thus, sedation techniques should be tailored for these patients.

01 Jan 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

On-site SERS analysis and intelligent multi-identification of fentanyl class substances by deep machine learning

Article

Author: Mao, Zhengsheng ; Jiang, Qiao-Yan ; Huang, Ping ; Zhang, Yuan ; Cao, Yue ; Wang, Li-Xiang ; Chen, Feng ; Sun, Yang ; Pian, Cong

As the types of fentanyl class substances continue to grow, a universal SERS sensor is essential for the application of discriminant detection of fentanyl substances. A new nanomaterial SERS sensor-Ag@Au NPs-paper was developed. The SERS sensitivity and stability of Ag@Au NPs-paper were investigated by using R6G molecule, and the results showed that Ag@Au NPs-paper has excellent performance. In combination with visual analysis and machine learning methods, Ag@Au NPs-paper has been successfully applied to the analysis of fentanyl class substances and the component identification of binary fentanyl mixtures, and thus it can be effectively used in food safety, environmental toxicants and other fields.

01 Jan 2025·CLINICA CHIMICA ACTA

Direct analysis in real time mass spectrometry (DART-MS/MS) for rapid urine opioid detection in a clinical setting

Article

Author: El-Khoury, Joe M ; Tran, Minh Nguyet ; Cassella-McLane, Gina ; Shang, Emily ; Choucair, Ibrahim

BACKGROUND AND AIMS:

Current laboratory methods for opioid detection involve an initial screening with immunoassays which offers efficient but non-specific results and a subsequent liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmation which offers accurate results but requires extensive sample preparation and turnaround time. Direct Analysis in Real Time (DART) tandem mass spectrometry is evaluated as an alternative approach for accurate opioid detection with efficient sample preparation and turnaround time.

MATERIALS AND METHODS:

DART-MS/MS was optimized by testing the method with varying temperatures, operation modes, extraction methods, hydrolysis times, and vortex times. The method was evaluated for 12 opioids by testing the analytical measurement range, percent carryover, precision studies, stability, and method-to-method comparison with LC-MS/MS.

RESULTS:

DART-MS/MS shows high sensitivity and specificity for the detection of 6-acetylmorphine, codeine, hydromorphone, oxymorphone, hydrocodone, naloxone, buprenorphine, norfentanyl, and fentanyl in urine samples. However, its performance was suboptimal for norbuprenorphine, morphine and oxycodone.

CONCLUSION:

In this proof-of-concept study, DART-MS/MS is evaluated for its rapid quantitative definitive testing of opioids drugs in urine. Further research is needed to expand its application to other areas of drug testing.

320

News (Medical) associated with Fentanyl

01 Oct 2024

·www.prnewswire.com

Truth Initiative and EVERFI from Blackbaud Join Forces with the Pennsylvania Office of the Attorney General to Address the Alarming Trend of Prescription Drug Overdoses among Young People

Youth opioid prevention event emphasized the importance of substance abuse prevention education for young people WASHINGTON and CHARLESTON, S.C., Oct. 1, 2024 /PRNewswire/ -- Opioid overdoses among young people have risen steadily in recent years. To address this alarming trend, Truth Initiative, the organization behind truth ®—the nationally recognized and proven-effective youth tobacco and opioid prevention campaigns—EVERFI ® from Blackbaud ®, the leader in social impact education, and the Pennsylvania Office of the Attorney General (OAG) hosted a youth opioid prevention event to empower students with the knowledge to make safe and healthy decisions about prescription drugs and increase understanding of the dangers of fentanyl and counterfeit pills. The event, held at Lower Dauphin High School in Hummelstown, Pennsylvania, on Sept. 30, featured in-depth discussions on opioid misuse, remarks from Pennsylvania Attorney General Michelle Henry, as well as engaging activities that highlighted the importance of youth substance abuse prevention education. One speaker at the event was Rebekkah Maher, a Recovery Advocate featured in Truth Initiative's "The Truth About Opioids" campaign and a powerful example of resilience and recovery. At 14, Maher became addicted to opioids after they were prescribed to her for an injury and later worked with Truth Initiative to share her story of recovery. "While working to get clean, I was fighting every single day, learning how to love myself, and rediscovering the potential of tomorrow. Long-term recovery is the hardest thing I've ever done — and it's something I'll do for the rest of my life," said Maher. She continues to share her story, hoping to prevent others from experiencing the hardships she endured. The event at Lower Dauphin High School built upon an ongoing partnership between the OAG, Truth Initiative, and EVERFI to provide students with access to Prescription Drug Safety: Know the truth, a free, digital curriculum from Truth Initiative and EVERFI that educates students about the dangers associated with misusing prescription medications, including counterfeit drugs containing fentanyl. "Equipping students with the knowledge and skills to prevent prescription drug misuse is crucial. By providing students with the tools to make safe and healthy decisions about prescription drugs and an understanding of the dangers of fentanyl and counterfeit pills, we are giving them the power to stay safe and protect others in their communities," said Amy Taylor, Chief Development and Engagement Officer. The youth opioid crisis continues to be a serious problem for communities across the U.S., including in Pennsylvania. A potent synthetic opioid, illegally manufactured fentanyl was involved in 84% of the more than 2,200 cases of reported adolescent drug overdose deaths that occurred from 2019 to 2021. The most recent Youth Risk Behavior Survey found that 12.2% of high school students nationally — and 9% of high school students in Pennsylvania — had misused prescription opioids in their lifetime, with nearly half indicating they had misused them in the past 30 days, according to the Centers for Disease Control and Prevention (CDC). In addition, overdose deaths by counterfeit pills more than doubled from 2019 to 2021, and over half of those who died were age 35 or younger. "While we may wish it wasn't necessary, the reality is that we have an obligation to ensure our youth are provided with trusted sources of education on topics like prescription drug safety. To make healthy decisions about their own medication use, students need to understand key concepts related to prescription drugs, safe use, refusal skills, and where to find resources," said Ellen Patterson, president and general manager, EVERFI from Blackbaud. "Our data indicates that education on this topic increases students' knowledge and understanding of these concepts, and we are proud to work with Truth Initiative and the Pennsylvania OAG to bring this education to students across the Commonwealth." Opioid misuse is a complex issue that needs to be addressed from various perspectives, including in the classroom. Prescription Drug Safety: Know the truth uses real-world scenarios and an authentic peer-to-peer voice to help students gain a better understanding of the growing youth fentanyl crisis and how to support others in situations involving prescription drug misuse and overdose. Students at the event engaged with the curriculum prior to the event as part of their health class. "Prescription opioids are highly addictive and pose a risk of being abused, oftentimes by people who begin taking medications for legitimate reasons and those closest to them," Attorney General Michelle Henry said. "Keeping unused or unneeded drugs out of Pennsylvania communities will always be a top priority of my office. I was honored to have a chance to share this message with the students of Lower Dauphin High School, as we have found young people are vulnerable to becoming addicted to these potent drugs." About Truth Initiative Truth Initiative is a national nonprofit public health organization committed to a future free from lifelong addiction, fostering healthier lives and a more resilient nation. Our mission is to prevent youth and young adult nicotine addiction and empower quitting for all. Through our evidence-based, market-leading cessation EX Program and the nationally recognized truth ® public education campaign, we are leading the fight against youth and young adult tobacco use, which threatens to put a new generation at risk of nicotine addiction. Our rigorous scientific research and policy studies, community and youth engagement programs supporting populations at high risk of using tobacco, and innovation in tobacco dependence treatment continue to contribute to ending one of the most critical public health battles of our time. Based in Washington, D.C., our organization was established and funded through the 1998 Master Settlement Agreement between attorneys general from 46 states, five U.S. territories, and the tobacco industry. To learn more, visit truthinitiative.org. About EVERFI from Blackbaud EVERFI® from Blackbaud® is an international technology company driving social impact through education to address the most challenging issues affecting society ranging from financial wellness to mental health to workplace conduct and other critical topics. Founded in 2008, EVERFI's Impact-as-a-Service™ solution and digital educational content have reached more than 45 million learners globally. In 2020, the company was recognized as one of the World's Most Innovative Companies by Fast Company and was featured on Fortune Magazine's Impact 20 List. The company was also named to the 2021 GSV EdTech 150, a list of the most transformative growth companies in digital learning. Blackbaud acquired EVERFI in December of 2021. To learn more about EVERFI, please visit everfi.com or follow us on Facebook, Instagram, LinkedIn, or X/Twitter @EVERFI. Blackbaud Forward-looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties, including statements regarding expected benefits of products and product features. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: general economic risks; uncertainty regarding increased business and renewals from existing customers; continued success in sales growth; management of integration of acquired companies and other risks associated with acquisitions; risks associated with successful implementation of multiple integrated software products; the ability to attract and retain key personnel; risks associated with management of growth; lengthy sales and implementation cycles, particularly in larger organization; technological changes that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC's website at or upon request from Blackbaud's investor relations department. All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc. SOURCE Truth Initiative WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

30 Sep 2024

·www.prnewswire.com

New Shatterproof National Poll: Majority of U.S. Adults Misunderstand and Hold Negative Perceptions of People with Substance Use Disorders

Majority of adults (74%) don't believe a person with a substance use disorder (SUD) is experiencing a chronic medical illness. Read the full results. NORWALK, Conn., Sept. 30, 2024 /PRNewswire/ -- A majority of U.S. adults demonstrate high levels of addiction stigma, according to new data released today by Shatterproof. The Shatterproof Addiction Stigma Index (SASI) is the largest and most expansive measurement tool designed to date to assess attitudes about substance use disorder (sometimes referred to as addiction) and people with SUDs. The data helps raise awareness about addiction stigma and how it impacts people with addiction, allows us to track progress over time and holds our nation accountable for ending addiction stigma. Currently, nearly 49 million Americans ages 12 and older are living with SUDs and less than 5% of people who need treatment for addiction will ever receive it, making this the nation's most urgent public health issue. While recent data has shown a decline in substance-related fatalities over the last year, these numbers are still alarmingly high. Addiction stigma is a critical driver of this crisis, contributing to social isolation and further discouraging help-seeking behavior from individuals hoping to manage this complex medical condition. While historically addiction stigma has been under-researched and largely unaddressed, the 2024 SASI report explores the perspective of one woman, Kaitlyn, and her journey with substance use to raise awareness of this issue and mobilize this country to take action. Addiction stigma is a set of negative attitudes and beliefs that often lead to unjust treatment of people with addiction. Doctors Brea Perry and Megan Bolton from the Irsay Institute at Indiana University played a role in supporting the research. Some key findings from the SASI include: 74% of respondents don't believe that a person with SUD is experiencing a chronic medical illness. 45% of respondents are unwilling to move next door to a person with SUD. 47% of respondents are unwilling to have a person with SUD as a close friend. 43% of respondents believe that medications for opioid use disorder (MOUD) is simply substituting one drug addiction for another. There are some hopeful findings. Nearly three in four respondents (73%) agree that fentanyl testing strips should be free and available as a key tool in preventing drug-related fatalities. These small strips of paper can detect the presence of fentanyl in different kinds of drugs and drug forms, like pills, powders and injectable substances, according to the CDC. Additionally, nearly 80% of respondents believe that more healthcare providers should offer MOUD so that they are easily accessible. They also believe that MOUD is an effective treatment for opioid use disorder (OUD). Also of note, nearly 80% of respondents feel that treatment strategies are more effective than time in prison for drug-related, non-violent crimes. And finally, 71% of adults personally support carrying naloxone (also known as Narcan), which is a medicine that rapidly reverses drug-related overdose symptoms and mitigates fatality. Importantly, the SASI outlines key actions for individuals to take to help shatter stigma and support their communities. These recommendations were informed by interviews with people impacted by SUD: Educate yourself and others. Seek out information about SUD, know how to identify and respond to an overdose and learn about the resources available. Share your story. Most Americans (54%) know someone with SUD. Stories connect us all and people can be part of the movement to end addiction stigma by sharing how substance use has impacted their lives. Shatterproof first co-developed the SASI with researchers at Indiana University in 2021 to better understand the public's knowledge, attitudes and beliefs regarding SUD. The 2024 findings are based on a survey of more than 8,000 U.S. adults ages 18 and older. The SASI, fielded in both English and Spanish, was administered March 27 through April 8, 2024, using Ipsos Public Affairs, a global market firm, on behalf of Shatterproof. Ipsos utilizes KnowledgePanel® for recruitment, which is the largest online panel relying on probability-based sampling techniques. "Stigma is pervasive and is silently destroying our communities. The primary purpose of the 2024 Shatterproof Addiction Stigma Index report is to humanize addiction, bring awareness to the devastating impacts of stigma, and urge our country to take collective action to reduce addiction-related stigma over time," said Courtney McKeon, senior vice president of the National Stigma Initiative, Shatterproof. "Societies take time to change and this movement to end addiction stigma is going to take a sustained and concreted effort. When we seek to understand and show compassion to those around us, we help create environments where people who use substances and people with substance use disorder feel supported in their journeys to navigate their medical condition." For millions of Americans and those who love them, ending addiction stigma is a matter of survival. Shatterproof has a mission to end stigma by working closely with state agencies, community organizations and individuals so that no one has to navigate the complexities of SUD alone. To learn more about SUD, find resources and take action, visit . ABOUT SHATTERPROOF: Shatterproof is a national nonprofit organization dedicated to transforming the addiction treatment system in the U.S. Shatterproof is focused on guiding society, especially families, through the complexities of a substance use disorder; informing the public on prevention, treatment and recovery from addiction; and educating the public to reduce addiction stigma to ensure that people who use substances or have a substance use disorder can live healthy and fulfilled lives. Find Shatterproof on Facebook, X and YouTube: @ShatterproofHQ or follow them on Instagram: @weareshatterproof. To learn more, visit . SOURCE Shatterproof WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

27 Sep 2024

·www.drugs.com

Upping Dose of Anti-Opioid Drug Might Work Better to Curb Addiction

FRIDAY, September 27, 2024 -- Patients with opioid use disorder who receive higher doses of a drug to treat their addiction are more likely to have positive results, a new study finds. Daily doses of the drug buprenorphine is a standard treatment for opioid use disorder, and the findings suggest that higher doses may be a better way to manage it. Researchers say this could be an important way to improve treatment for people who use fentanyl, a major cause of opioid overdose. "As the overdose crisis evolves, particularly with the rise of fentanyl, it is crucial to investigate how to best adapt and deliver the lifesaving and evidence-based treatments for opioid use disorder that we have available," said Dr. Nora Volkow , director of the National Institute on Drug Abuse (NIDA). For the study, researchers reviewed insurance claims data from more than 35,000 patients who entered buprenorphine treatment between 2016 and 2021. During that time, 12.5% required emergency or inpatient care for mental health issues. The U.S. Food and Drug Administration recommends a daily dose of 16 milligrams (mg) of buprenorphine. In the first year after receiving treatment, patients who took 16 to 24 mg of buprenorphine took 20% longer to have a subsequent ER or inpatient hospital visit than those receiving 8 to 16 mg a day. Meanwhile, those taking more than 24 mg of buprenorphine a day went 50% longer before having an emergency or inpatient stay compared to those receiving 8 to 16 mg a day, the study found. Studies have shown that doses of more than 16 mg of buprenorphine are safe and well-tolerated. "The findings add to the growing evidence that higher doses of buprenorphine may have meaningful health impacts for people with opioid use disorder," Volkow said in a NIDA news release. The availability of potent fentanyl, a synthetic opioid that is roughly 50 times stronger than heroin, has accelerated the search for solutions to a nationwide opioid epidemic. In 2022 alone, of nearly 108,000 overdose deaths reported nationwide, almost 70% were primarily due to fentanyl. That trend has also raised questions about whether existing dosing guidelines for buprenorphine should be modified. Researchers said higher doses of buprenorphine may be needed to counteract the more severe withdrawal symptoms, cravings and tolerance associated with fentanyl use. They said removing barriers to accessing higher doses -- including insurance policies and state laws -- will be a key to ensuring that all patients receive effective care. "Preventing or delaying the need for high-intensity, urgent health care among people with opioid use disorder has tremendous benefits on health and recovery," said study co-author Dr. Bradley Stein , director of the opioid policy, tools and information center at the RAND Institute, a health policy think tank. Researchers noted that data used in the study were culled from one commercial insurer and do not include uninsured people or those with government coverage. In addition, the sample was made up overwhelmingly of white, non-Hispanic patients. The findings were published Sept. 25 in JAMA Network Open . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

100 Deals associated with Fentanyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00320	Fentanyl	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	JP	Janssen Pharmaceutical KK	01 Feb 2011
Acute Pain	US	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Chronic Pain	US	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Hypoventilation	US	Janssen Pharmaceuticals, Inc.	07 Aug 1990
Pain, Postoperative	US	Janssen Pharmaceuticals, Inc.	07 Aug 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucositis	Phase 3	US	INSYS Therapeutics, Inc.	01 Oct 2009
Solid tumor	Phase 3	US	INSYS Therapeutics, Inc.	01 Oct 2009
Stomatitis	Phase 3	US	INSYS Therapeutics, Inc.	01 Oct 2009
Low Back Pain	Phase 3	JP	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Osteoarthritis	Phase 3	JP	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Complex Regional Pain Syndromes	Phase 3	JP	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neuralgia, Postherpetic	Phase 3	JP	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain Disorder	Phase 3	JP	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain, Intractable	Phase 3	-	Janssen Pharmaceuticals, Inc.	01 May 2005
Neoplasms	Phase 3	-	ALZA Corp.	01 May 1986

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	tvqhznsvdq(cazuarjlln) = hpxmpsbvyr lfnzczoohw (byfpquewxg, rpuoddltas - haouddvwgo) View more	-	17 Oct 2024
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	gkxpfhjual(cmtowmiqka) = avsvfusrto xjfyrznikd (cicrpfnfsz, ddbkufrhgu - nyodizfcvj) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	gkxpfhjual(cmtowmiqka) = mmxbydcmxe xjfyrznikd (cicrpfnfsz, ebvburqztj - prwwysntxb) View more
NCT03115151 (CTgov)	Phase 4	Pain	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	zhhizlyazn(aljemxkpns) = mwmkeyyxdi qsfgdxhhwy (uoopbanxtv, feaytjfwuj - ehmzqnokox) View more	-	26 Oct 2023
				Hydromorphone (Intravenous Patient-controlled Analgesia)	zhhizlyazn(aljemxkpns) = rfjaibhwhb qsfgdxhhwy (uoopbanxtv, wwaeixuogq - vbscoainec) View more
ICML2023	Not Applicable	18 FDG	-	Fentanyl pre-treatment	datumcluud(gqmopgiuty) = ytvznqfkio mfecjftgru (wddrhivilv )	Positive	09 Jun 2023
				No fentanyl pre-treatment	datumcluud(gqmopgiuty) = hnfhnikybw mfecjftgru (wddrhivilv )
P12-11.015 (AAN2023)	Not Applicable	Parkinson Disease	1,581	Fentanyl patch	ovepxufkpe(phqqewvvhn) = involuntary, nonsuppressible writhing motion of the face, trunk and all limbs osonqubhxo (ptqkprexof ) View more	Negative	25 Apr 2023
NCT01362998 (CTgov)	Not Applicable	Analgesia	2	Preservative free morphine (Preservative Free Morphine)	srrmhfjddk(cdaiweslla) = vwowsnvwdt jmkihkibav (pwbybbvuve, mkhemyfomt - jkrfvxdwrc) View more	-	14 Nov 2022
				Fentanyl (Fentanyl Infusion)	xhnmwcxvsu(gzgalgnart) = bznwefuegf aldwizyoex (ottayzfzrd, orugyivmad - vggjqwbauf) View more
Pubmed	Not Applicable	-	178	Fentanyl	slhelieesl(wyeiijrkhq) = azlnavwuag ngadvdasrc (ajcwqqugub ) View more	-	28 Sep 2022
				Esketamine 0.2 mg/kg	urfemveewh(ilfqfgrqzy) = uqkbwpdezi usgxoxoacg (ladlgyhbkq ) View more
NCT00580489 (CTgov)	Not Applicable	Pain \| Drug-Related Side Effects and Adverse Reactions	204	fentanyl+morphine (Arm C Morphine)	gbmosdfrid(rufqskaxkg) = chkpjakvry wzhlqjauww (aotjtildea, czvwhammuf - qtcilhmkix)	-	16 Aug 2022
				fentanyl+morphine (Arm D Fentanyl)	gbmosdfrid(rufqskaxkg) = ikqxwdccjq wzhlqjauww (aotjtildea, ziuxqpiggl - gzitaknbqo)
NCT03882788 (NDO, CTgov)	Not Applicable	Heart Defects, Congenital \| Maternal anesthesia and analgesia affecting fetus or newborn \| Neurodevelopmental Disorders	153	Fentanyl (high dose) (Narcotic Based Anesthesia)	xjbsdzgbqy(vcqffzyaxa) = crshetpnna yshneiffmq (amqshffmcd, eqzznlseqq - aukqvguqnn) View more	-	09 May 2022
				Fentanyl (low dose)+Isoflurane (Volatile Anesthesia)	xjbsdzgbqy(vcqffzyaxa) = eeapyttzqd yshneiffmq (amqshffmcd, adontzdwln - cilrlggkvr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis